Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5684 Target Snapshot

Muscle, skeletal receptor tyrosine-protein kinase · SINGLE PROTEIN · Homo sapiens

963Compounds
241Assays
7Approved Drugs
150.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt O15146. Use UniProt O15146 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt O15146 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Muscle, skeletal receptor tyrosine-protein kinase as ChEMBL target CHEMBL5684, mapped to UniProt O15146. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Muscle, skeletal receptor tyrosine-protein kinase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5684
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O15146
Muscle, skeletal receptor tyrosine-protein kinase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Muscle, skeletal receptor tyrosine-protein kinase is the right protein anchor across sources, using UniProt O15146 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelMuscle, skeletal receptor tyrosine-protein kinase
UniProt AccessionO15146
Component TypeProtein
Sequence Length869 aa

Muscle, skeletal receptor tyrosine-protein kinase

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Muscle, skeletal receptor tyrosine-protein kinase, mapped to UniProt O15146. Sequence length is 869 aa.

Mapped IDO15146
Review nameMuscle, skeletal receptor tyrosine-protein kinase
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

7
Approved
3
Phase III
8
Phase II
3
Phase I
Assay Mix

Activity Type Distribution

IC5026.0
KI1.0
KD123.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL574738 8.51 Kd 3.1 Preclinical
CHEMBL388978 8.42 IC50 3.8 Preclinical
CHEMBL601719 8.04 IC50 9.1 Approved
CHEMBL223360 8.0 Kd 10.0 Clinical
CHEMBL5423601 7.89 IC50 12.83 Preclinical
CHEMBL1230609 7.89 Kd 13.0 Clinical
CHEMBL4212531 7.28 IC50 53.0 Preclinical
CHEMBL388978 7.07 Kd 86.0 Preclinical
CHEMBL1721885 7.0 Kd 100.0 Clinical
CHEMBL475251 7.0 Kd 100.0 Clinical
Distribution

pChEMBL Value Distribution

3
5.0
4
5.5
17
6.0
14
6.5
7
7.0
2
7.5
4
8.0
2
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

QUIZARTINIB
CHEMBL576982
Approved 2023
FEDRATINIB
CHEMBL1287853
Approved 2019
NINTEDANIB
CHEMBL502835
Approved 2014
CRIZOTINIB
CHEMBL601719
Approved 2011
SUNITINIB
CHEMBL535
Approved 2006
SORAFENIB
CHEMBL1336
Approved 2005
Assay Landscape

Assay Landscape

241
Total Assays
34
Tested Compounds
1
Assay Types
Binding — 241 assays, 34 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 201 30 6.6
assay format 32 4 7.0
cell-based format 8 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine